Efficacy of Ustekinumab and Vedolizumab Among Postoperative Crohn&apos;s Disease Patients as Postoperative Prophylaxis and Rescue Therapy: Real-world Data

Inflammatory Bowel Disease

Real-World Long-Term Persistence and Surgical Procedure-Free Period Among Bio-naïve Patients with Crohn's Disease and Fistula Initiated on Ustekinumab

Adv Ther

Zhdanava M, Kachroo S, Boonmak P, Burbage S, Shah A, Lefebvre P, Kerner C, Pilon D

doi: 10.1007/s12325-024-02963-1

Inflammatory Bowel Disease

Real-World Treatment Persistence Among Advanced Therapy-Naïve or -Experienced Patients with Ulcerative Colitis Initiated on Ustekinumab or Adalimumab

Adv Ther

Zhdanava M, Kachroo S, Boonmak P, Burbage S, Shah A, Korsiak J, Lefebvre P, Kerner C, Pilon D

doi: 10.1007/s12325-024-02942-6

Inflammatory Bowel Disease

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

J Crohns Colitis

D'Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, Loftus EV Jr, Kobayashi T, Elsharkawi W, Miceli R, Ahmed S, Luo Y, Napoli A, Vaile J, Dornic Q, Patel A, Schreiber S

doi: 10.1093/ecco-jcc/jjaf080

Inflammatory Bowel Disease

Comparative Safety and Effectiveness of Ustekinumab and Anti-TNF in Elderly Crohn's Disease Patients

Inflamm Bowel Dis

Gebeyehu GG, Broglio G, Liu E, Limdi JK, Selinger C, Fiske J, Razanskaite V, Smith PJ, Flanagan PK, Subramanian S

doi: 10.1093/ibd/izae174

Further Publications

A Prospective Comparison of Ustekinumab and Anti-TNF Therapy in the Treatment of Crohn's-like Disease of the Pouch

Am J Gastroenterol

Barnes EL, Raffals L, Qazi T, Deepak P, Chang S, Beniwal-Patel P, Higgins PD, Cross RK, Barr JI, Anderson C, Long MD, Herfarth HH, Dubinsky M, Kappelman MD, Kayal M

doi: 10.14309/ajg.0000000000003608

Inflammatory Bowel Disease

Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial

Lancet Gastroenterol Hepatol

D'Haens G, Taxonera C, Lopez-Sanroman A, Nos P, Danese S, Armuzzi A, Roblin X, Peyrin-Biroulet L, West R, Mares WGN, Duijvestein M, Gecse KB, Feagan BG, Zou G, Hulshoff MS, Mookhoek A, Oldenburg L, Clasquin E, Bouhnik Y, Laharie D

doi: 10.1016/S2468-1253(24)00317-0

Inflammatory Bowel Disease

Real-World Effectiveness and Safety of Upadacitinib in Crohn's disease: A Multi-Centre Study

Clin Gastroenterol Hepatol

Devi J, Xu A, Stone M, Patel A, Khan A, Reddy N, Klein J, Chowla N, Benson C, Luu BC, Huang K, Jaiprada F, Fenster M, Ungaro R, Pekow J, Johnson AM, Yarur AJ, Shukla R, Huecker J, Bishu S, REBOOT IBD consortium, Deepak P

doi: 10.1016/j.cgh.2025.01.012

Inflammatory Bowel Disease

Placebo rates in Crohn's disease randomized clinical trials: An individual patient data meta-analysis

Gastroenterology

Solitano V, Hogan M, Singh S, Danese S, Peyrin-Biroulet L, Zou G, Yuan Y, Sands BE, Feagan BG, Dulai PS, Narula N, Ma C, Jairath V

doi: 10.1053/j.gastro.2024.10.009

Inflammatory Bowel Disease

Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment-real world comparative effectiveness from German claims data

BMC Gastroenterol

Dignass A, Teich N, Kaiser S, Sünwoldt J, Dünweber C, Weinhold I, Borchert J, Kudernatsch R

doi: 10.1186/s12876-025-04022-7

Related content

Real-World Long-Term Persistence and Surgical Procedure-Free Period Among Bio-naïve Patients with Crohn's Disease and Fistula Initiated on Ustekinumab

Real-World Treatment Persistence Among Advanced Therapy-Naïve or -Experienced Patients with Ulcerative Colitis Initiated on Ustekinumab or Adalimumab

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

Comparative Safety and Effectiveness of Ustekinumab and Anti-TNF in Elderly Crohn's Disease Patients

A Prospective Comparison of Ustekinumab and Anti-TNF Therapy in the Treatment of Crohn's-like Disease of the Pouch

Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial

Real-World Effectiveness and Safety of Upadacitinib in Crohn's disease: A Multi-Centre Study

Placebo rates in Crohn's disease randomized clinical trials: An individual patient data meta-analysis

Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment-real world comparative effectiveness from German claims data